China Tongfang announced that Atom Hi-Tech, a subsidiary of the company, and Novartis Pharma Technology Co., Ltd. formally signed a commercial cooperation agreement with Powett. Pavito is the first and currently the only approved radioligand therapy drug targeting PSMA in China. It is mainly used to treat advanced prostate cancer. The partnership aims to provide healthcare institutions and patients with customized Piweto product supply and solutions to benefit more patients.

China Tongfang announced that Atom Hi-Tech, a subsidiary of the company, and Novartis Pharma Technology Co., Ltd. formally signed a commercial cooperation agreement with Powett. Pavito is the first and currently the only approved radioligand therapy drug targeting PSMA in China. It is mainly used to treat advanced prostate cancer. The partnership aims to provide healthcare institutions and patients with customized Piweto product supply and solutions to benefit more patients.